The difference in the sensitivity to MEK inhibitors between RAS- and B-Raf-mutant cancers might arise from the level of dependency on Erk-mediated mTORC1 activation in tumors bearing RAS mutations [94]. The gene discussed is BRAF; the disease is cancer.